Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001855763-24-000015
Filing Date
2024-10-02
Accepted
2024-10-02 15:45:19
Documents
1
Period of Report
2024-10-01

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primary_doc.html 3  
1 PRIMARY DOCUMENT primary_doc.xml 3 2829
  Complete submission text file 0001855763-24-000015.txt   4412
Mailing Address 100 - 740 MCCURDY ROAD KELOWNA A1 V1X 2P7
Business Address 100 - 740 MCCURDY ROAD KELOWNA A1 V1X 2P7 250-765-6424
Lexaria Bioscience Corp. (Issuer) CIK: 0001348362 (see all company filings)

EIN.: 202000871 | State of Incorp.: NV | Fiscal Year End: 0831
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 406 NATALIE LANE DANVILLE CA 94506
Business Address
Shankman Michael Elliot (Reporting) CIK: 0002035175 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39874 | Film No.: 241346965